Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05156996 · ClinicalTrials.gov registry record
A Prospective Real-World Multi-Center Post-Market Observational Evaluation of Supersaturated O2 Therapy Using the TherOx® Downstream® System
A clinical trial, sponsored by TherOx.
- Terminated
- Registry status
- 6
- Enrollment target
NCT05156996 is a clinical trial that was terminated before completion, run by TherOx. The registered enrollment target is 6 participants.
The verdict
NCT05156996 was terminated before completion, sponsored by TherOx.
- TERMINATED
- Registry status
- 6 participants
- Enrollment target
Study Summary
The purpose of this study is to collect real-world data on the TherOx DownStream System® to assess the effectiveness and cost- effectiveness of SSO2 Therapy, compared with PCI alone for treatment of patients with acute anterior MI.
Interventions
- DEVICE Supersaturated O2 Therapy of the Therox Downstream System®
- PROCEDURE PCI alone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2022-12-04 |
| Est. Completion | 2024-04-24 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05156996
The ClinicalTrials.gov registry entry for NCT05156996 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is TherOx, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Supersaturated O2 Therapy of the Therox Downstream System® is the first listed.
NCT05156996 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05156996 about?
NCT05156996 is a clinical study titled "A Prospective Real-World Multi-Center Post-Market Observational Evaluation of Supersaturated O2 Therapy Using the TherOx® Downstream® System". The purpose of this study is to collect real-world data on the TherOx DownStream System® to assess the effectiveness and cost- effectiveness of SSO2 Therapy, compared with PCI alone for treatment of patients with acute anterior MI.
What is the current status of trial NCT05156996?
This trial is currently terminated. The enrollment target is 6 participants. The study started on 2022-12-04. Estimated completion is 2024-04-24.
What interventions are being tested in trial NCT05156996?
The interventions under investigation include: Supersaturated O2 Therapy of the Therox Downstream System® (DEVICE), PCI alone (PROCEDURE).
Who is sponsoring clinical trial NCT05156996?
This trial is sponsored by TherOx, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.